<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:17:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9949683" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9949683</identifier>
        <datestamp>2023-02-23</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">9005373</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">1697</journal-id>
              <journal-id journal-id-type="nlm-ta">Eur J Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur J Cancer</journal-id>
              <journal-title-group>
                <journal-title>European journal of cancer (Oxford, England : 1990)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0959-8049</issn>
              <issn pub-type="epub">1879-0852</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9949683</article-id>
              <article-id pub-id-type="pmcid">PMC9949683</article-id>
              <article-id pub-id-type="pmc-uid">9949683</article-id>
              <article-id pub-id-type="pmid">35568679</article-id>
              <article-id pub-id-type="pmid">35568679</article-id>
              <article-id pub-id-type="doi">10.1016/j.ejca.2022.03.042</article-id>
              <article-id pub-id-type="manuscript">nihpa1870978</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Brooke E.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Armstrong</surname>
                    <given-names>Andrew J.</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Bono</surname>
                    <given-names>Johann</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sternberg</surname>
                    <given-names>Cora N.</given-names>
                  </name>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ryan</surname>
                    <given-names>Charles J.</given-names>
                  </name>
                  <xref rid="A7" ref-type="aff">g</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scher</surname>
                    <given-names>Howard I.</given-names>
                  </name>
                  <xref rid="A8" ref-type="aff">h</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Matthew R.</given-names>
                  </name>
                  <xref rid="A9" ref-type="aff">i</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rathkopf</surname>
                    <given-names>Dana</given-names>
                  </name>
                  <xref rid="A10" ref-type="aff">j</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Logothetis</surname>
                    <given-names>Christopher J.</given-names>
                  </name>
                  <xref rid="A11" ref-type="aff">k</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chi</surname>
                    <given-names>Kim N.</given-names>
                  </name>
                  <xref rid="A12" ref-type="aff">l</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Robert J.</given-names>
                  </name>
                  <xref rid="A13" ref-type="aff">m</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saad</surname>
                    <given-names>Fred</given-names>
                  </name>
                  <xref rid="A14" ref-type="aff">n</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Porre</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref rid="A15" ref-type="aff">o</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tran</surname>
                    <given-names>NamPhuong</given-names>
                  </name>
                  <xref rid="A16" ref-type="aff">p</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hu</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref rid="A17" ref-type="aff">q</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gillessen</surname>
                    <given-names>Silke</given-names>
                  </name>
                  <xref rid="A18" ref-type="aff">r</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carles</surname>
                    <given-names>Joan</given-names>
                  </name>
                  <xref rid="A19" ref-type="aff">s</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fizazi</surname>
                    <given-names>Karim</given-names>
                  </name>
                  <xref rid="A20" ref-type="aff">t</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Joshua</surname>
                    <given-names>Anthony M.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="CR1" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>Princess Margaret Cancer Centre, Toronto, Canada</aff>
              <aff id="A2"><label>b</label>Faculty of Medicine, University of New South Wales, Kensington, Australia</aff>
              <aff id="A3"><label>c</label>Kinghorn Cancer Centre, St Vincents Hospital, Darlinghurst, Sydney, Australia</aff>
              <aff id="A4"><label>d</label>Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA</aff>
              <aff id="A5"><label>e</label>The Institute of Cancer Research and Royal Marsden Hospital, London, UK</aff>
              <aff id="A6"><label>f</label>Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY 10021, USA</aff>
              <aff id="A7"><label>g</label>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA</aff>
              <aff id="A8"><label>h</label>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</aff>
              <aff id="A9"><label>i</label>Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA</aff>
              <aff id="A10"><label>j</label>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA</aff>
              <aff id="A11"><label>k</label>Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
              <aff id="A12"><label>l</label>BC Cancer, Vancouver, Canada</aff>
              <aff id="A13"><label>m</label>Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK</aff>
              <aff id="A14"><label>n</label>Department of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada</aff>
              <aff id="A15"><label>o</label>Janssen R&amp;D, Beerse, Belgium</aff>
              <aff id="A16"><label>p</label>Janssen R&amp;D, Los Angeles, CA, USA</aff>
              <aff id="A17"><label>q</label>Janssen LLC. Raritan, New Jersey, USA</aff>
              <aff id="A18"><label>r</label>Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland and Universita Della Svizzera Italiana, Lugano, Switzerland and University of Manchester, UK</aff>
              <aff id="A19"><label>s</label>Vall D’Hebron Institute of Oncology, Vall D’Hebron University Hospital, Barcelona, Spain</aff>
              <aff id="A20"><label>t</label>Institut Gustave Roussy, University of Paris Saclay, Villejuif, France</aff>
              <author-notes>
                <corresp id="CR1"><label>*</label><italic toggle="yes">Corresponding author</italic>: Department of Medical Oncology, Kinghorn Cancer Centre, St Vincents Hospital, 370 Victoria St, Darlinghurst, 2010, Sydney, Australia. <email>anthony.joshua@svha.org.au</email> (A.M. Joshua).</corresp>
                <fn fn-type="con" id="FN1">
                  <p id="P1">Author contribution</p>
                  <p id="P2">Conceptualisation; BEW, AA, SG, JC, KF, AMJ; Data curation; BEW, PDEP, NT, PH, AMJ; Formal analysis; NT; Funding acquisition; N/A; Investigation; ALLMethodology; BEW, PDEP, NT, PH, AMJ; Project administration; N/A; Resources; N/A; Software; N/A; Supervision; N/A; Validation; ALL; Visualisation; N/A; Roles/Writing – original draft; ALL; Writing – review &amp; editing ALL.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>13</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <volume>170</volume>
              <fpage>296</fpage>
              <lpage>304</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <sec id="S1">
                  <title>Background:</title>
                  <p id="P3">The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear.</p>
                </sec>
                <sec id="S2">
                  <title>Objective:</title>
                  <p id="P4">To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR.</p>
                </sec>
                <sec id="S3">
                  <title>Design, setting and participant:</title>
                  <p id="P5">COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ<sup>2</sup> test.</p>
                </sec>
                <sec id="S4">
                  <title>Results:</title>
                  <p id="P6">In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48–0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47–0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62–0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62–0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68–0.88).</p>
                </sec>
                <sec id="S5">
                  <title>Conclusion:</title>
                  <p id="P7">Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Metastatic castration-resistant prostate cancer</kwd>
                <kwd>Metformin</kwd>
                <kwd>Statins</kwd>
                <kwd>Abiraterone acetate</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="S6">
              <label>1.</label>
              <title>Introduction</title>
              <p id="P8">The COU-AA-302 and COU-AA-301 studies demonstrated improved overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate plus prednisone/prednisolone (AAP) both before and after docetaxel chemotherapy, respectively, establishing new treatment paradigms [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. Despite this advance, the long-term prognosis of these patients remains limited and additional treatments to prolong survival are still needed.</p>
              <p id="P9">Over the last 15 years, there has been increasing interest in the potential anti-neoplastic effect of commonly prescribed drugs most notably metformin, for which a reduced cancer incidence was first noted in population data in 2005 [<xref rid="R3" ref-type="bibr">3</xref>]. That was followed by several epidemiological studies showing a reduction in prostate cancer incidence and improved OS among patients receiving metformin [<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>]. In the largest meta-analysis to date that included 30 cohorts and over 1.6 million patients, patients with prostate cancer receiving metformin had improved OS compared to those who did not [<xref rid="R8" ref-type="bibr">8</xref>], a finding that remains controversial and may be subject to bias [<xref rid="R9" ref-type="bibr">9</xref>]. How the drug affects tumour growth is unclear but possibilities include activating AMPK that leads to inhibition of mTOR signalling, reduced fatty acid synthesis, and induction of cyclin-dependent kinase induced autophagy and apoptosis [<xref rid="R10" ref-type="bibr">10</xref>].</p>
              <p id="P10">Similarly, adjunctive favourable effects of statins on prostate cancer progression have been reported. In one cohort of 14,000 men with the disease, statin use prior to diagnosis was associated with lower rates of prostate cancer-related deaths [<xref rid="R11" ref-type="bibr">11</xref>]. Cholesterol is a precursor to androgen synthesis, and the reduced availability of cholesterol may in turn reduce androgen production and the secretion of pro-inflammatory cytokines [<xref rid="R12" ref-type="bibr">12</xref>], slowing disease progression.</p>
              <p id="P11">The objective of this study is to examine whether metformin and statin use in men being receiving AAP for mCRPC in the COU-AA-301 and COU-AA-302 trials improved OS and prostate specific antigen response rates (PSA-RR).</p>
            </sec>
            <sec id="S7">
              <label>2.</label>
              <title>Methods</title>
              <p id="P12">We performed a post-hoc secondary analysis of data collected in the COU-AA-301 and COU-AA-302 trials. In COU-AA-301, patients treated with post-docetaxel were randomised 2:1 to either AA (1000 mg) daily plus 5 mg bd prednisone or 5 mg bd prednisone alone. COU-AA-302 randomised chemotherapy-naïve patients in a 1:1 fashion to either AA (1000 mg) daily plus 5 mg bd of prednisone or 5 mg bd of prednisone alone. Detailed methods for these studies have been published previously [<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]. We retrospectively extracted data on concomitant use of metformin and statins, recorded at study entry and examined for associations with (1) OS and (2) PSA-RR.</p>
              <p id="P13">As per the study protocols, PSA-RR was defined as the proportion of patients achieving a decrease in PSA of at least 50% from the baseline PSA value confirmed at least 4 weeks or more after the initiation of treatment. Baseline variables were summarised by the presence or absence of concomitant medication. We examined for any differences between groups using the χ<sup>2</sup> for categorical variables and student’s t test for continuous variables. Adverse event (AE) data for COU-AA-301 and 302, summarised by the use of concomitant medications and by treatment arm were tabulated, however, no statistical testing was performed due to the risk of multiple testing. OS was estimated using Kaplan-Meier methods and compared using the log rank test. Cox proportional hazards models were used to estimate the hazards ratio (HR) for OS by each concomitant medication. Variables chosen for inclusion in multivariate modelling were based on prior prognostic models predicting PFS or OS in patients with mCRPC treated with AAP either before [<xref rid="R13" ref-type="bibr">13</xref>] or after docetaxel [<xref rid="R14" ref-type="bibr">14</xref>]. Differences in the proportion of those with a PSA response were compared using χ<sup>2</sup>. A random effects model was used to pool unadjusted estimates of effect size for OS. Throughout the study, a two-tailed p &lt; 0.05 was considered statistically significant for further hypothesis generation.</p>
            </sec>
            <sec id="S8">
              <label>3.</label>
              <title>Results</title>
              <p id="P14">Among the 1195 patients enrolled in COU-AA-301, 104 were reported to be receiving metformin (73 (9.2%) in the AAP group and 31 (7.8%) in the placebo group), and 339 (28.4%) to be receiving statins (236 (29.6%) in the AAP group and 103 (25.9%) in the placebo group). Among the 1088 patients enrolled in COU-AA-302, 134 were reported to be receiving metformin (66 (12.1%) in the AAP group and 68 (12.5%) in the placebo group), and 436 (40.1%) to be receiving statins (229 (41.9%) in the AAP group and 207 (38.2%) in the placebo group). Few patients in each group received combination metformin and statin, limiting any further analysis (COU-301-AAP n = 45; COU-301-placebo n = 15; COU-302-AAP n = 49; COU-302-placebo n = 48). Baseline characteristics stratified by statin/metformin use are presented in <xref rid="SD2" ref-type="supplementary-material">Supplemental Tables 1</xref> and <xref rid="SD2" ref-type="supplementary-material">2</xref>. Generally, patients taking statins or metformin had a higher rate of pre-existing cardiovascular disease and a higher body mass index.</p>
              <sec id="S9">
                <label>3.1.</label>
                <title>The effect of metformin/statins on toxicity rates in each arm of COU-AA-301 and COU-AA-302</title>
                <p id="P15">Total number of AE and grade 3 or 4 AE are presented in <xref rid="SD2" ref-type="supplementary-material">Supplemental Tables 3</xref>-<xref rid="SD2" ref-type="supplementary-material">6</xref> and are broadly similar between all groups. Although absolute numbers were extremely low, there was a higher percentage of G3/4 cardiac disorder and G3/4 hypokalaemia in patients taking statins with AAP than those that did not take statins with AAP (COU-AA-301 – Cardiac disorder 8.5% (takers) versus 3.8% (non-takers), hypokalaemia 6.8% (takers) versus 4.3% (non-takers); COU-AA-302 – Cardiac disorder 8.7% (takers) versus 3.2% (non-takers), hypokalaemia 3.9% (takers) versus 1.6% (non-takers).</p>
              </sec>
              <sec id="S10">
                <label>3.2.</label>
                <title>The effect of metformin on clinical outcomes</title>
                <p id="P16">In COU-AA-301-AAP, there was no definitive association with the median OS in those prescribed metformin (19.4 versus 15.6 months, HR 0.76 95% CI 0.55–1.05) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F1" ref-type="fig">Fig. 1</xref>). However, the trend remained in multivariate analysis after adjusting for liver metastases, ECOG score, albumin, LDH and alkaline phosphatase levels (adjHR 0.71, 95% CI 0.5–1.006) (<xref rid="T2" ref-type="table">Table 2</xref>). The proportion of patients with PSA-RR was greater among the metformin takers than non-takers in the AAP arm (41.1% versus 28.6%) (<xref rid="T3" ref-type="table">Table 3</xref>). In COU-AA-301-placebo, metformin was not associated with a prolonged OS in univariate (14.0 versus 11.1 months, HR 0.85 95% CI 0.54–1.32) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F1" ref-type="fig">Fig. 1</xref>) or multivariate analysis (<xref rid="T2" ref-type="table">Table 2</xref>). There was no difference in PSA-RR by metformin use status (3.2% versus 5.8%) (<xref rid="T3" ref-type="table">Table 3</xref>).</p>
                <p id="P17">In COU-AA-302-AAP, there was no association with OS by metformin use on univariate analysis (HR 0.81 95% CI 0.48–1.36) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F2" ref-type="fig">Fig. 2</xref>). After adjusting for baseline factors including Brief Pain Inventory (BPI), age, LDH, alkaline phosphatase, bone metastases and baseline PSA, metformin was associated with prolonged OS (adjHR 0.69 95% CI 0.4–0.98) (<xref rid="T2" ref-type="table">Table 2</xref>). The proportion of patients with PSA-RR was also greater in those prescribed metformin (72.7% versus 60.0%) (<xref rid="T2" ref-type="table">Table 2</xref>). In COU-AA-302-placebo, there were no significant difference in PSA-RR (27.9% versus 23.3%) or OS by metformin use (HR 0.68 95% CI 0.42–1.11) (<xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T3" ref-type="table">3</xref> and <xref rid="F2" ref-type="fig">Fig. 2</xref>). However, in multivariate analysis, metformin was associated with prolonged OS (adjHR 0.66 95% CI 0.47–0.93) (<xref rid="T2" ref-type="table">Table 2</xref>).</p>
                <p id="P18">In summary, the use of metformin in COU-AA-301 was not associated with significant improvement in OS (albeit a trend) but there was an increased PSA-RR in those randomised to AAP, but not in those randomised to placebo. The use of metformin in COU-AA-302 was associated with improved OS in multivariate analysis and increased PSA-RR in those randomised to AAP. In COU-AA-302-placebo, there was no difference in PSA-RR, but an association with metformin use and a prolonged OS was seen. In pooling HR across both studies and treatment arms, OS was prolonged among those treated with metformin (HR 0.77, 95% CI 0.62–0.95) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 1</xref>).</p>
              </sec>
              <sec id="S11">
                <label>3.3.</label>
                <title>The effect of statins on clinical outcomes</title>
                <p id="P19">In COU-AA-301-AAP, concurrent statin use was associated with a longer median OS (17.6 versus 15.3 months, HR 0.76 95% CI 0.63–0.93) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F3" ref-type="fig">Fig. 3</xref>). This association remained significant after adjusting for liver metastases, ECOG score, albumin, LDH, alkaline phosphatase and time from LHRH use to relapse &lt;36 months (adjHR 0.76 95% CI 0.62–0.93) (<xref rid="T2" ref-type="table">Table 2</xref>). There was a higher PSA-RR among statin users (33.9% versus 28.0%) (<xref rid="T3" ref-type="table">Table 3</xref>). In COU-AA-301-placebo, the median OS was similar between statin user and non-user (13.2 versus 10.7 months) in both the univariate (HR 0.81 95% CI 0.62–1.07) and adjusted models (adjHR 0.96 95% CI 0.72–1.27) (<xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T2" ref-type="table">2</xref> and <xref rid="F3" ref-type="fig">Fig. 3</xref>). There was no difference in PSA-RR by statins use (4.8% versus 5.8%) (<xref rid="T3" ref-type="table">Table 3</xref>).</p>
                <p id="P20">In COU-AA-302-AAP, there was no difference in OS in patients prescribed statins in either univariate or multivariate models (adjHR 1.00 95% CI 0.8–1.2), nor was there a difference in PSA-RR (60.7% versus 62.1%) (<xref rid="T1" ref-type="table">Tables 1</xref>-<xref rid="T3" ref-type="table">3</xref> and <xref rid="F4" ref-type="fig">Fig. 4</xref>). In COU-AA-302-placebo, median OS was longer among those prescribed statins in univariate analysis (HR 0.70 95% CI 0.52–0.96) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F4" ref-type="fig">Fig. 4</xref>) but not in adjusted analysis (adjHR 0.88 95% CI 0.71–1.08) (<xref rid="T2" ref-type="table">Table 2</xref>). There was no difference in PSA-RR (23.3% versus 24.3%) (<xref rid="T3" ref-type="table">Table 3</xref>).</p>
                <p id="P21">In summary, in COU-AA-301 statin use was associated with an improved OS and an increased PSA-RR in those randomised to AAP but not placebo. In COU-AA-302, there was no difference in OS or PSA response in the AAP or placebo groups between statin users and non-users. When pooling HR across all study and treatment arms, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68–0.88) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 2</xref>).</p>
              </sec>
            </sec>
            <sec id="S12">
              <label>4.</label>
              <title>Discussion</title>
              <p id="P22">The addition of metformin or statins to standard of care AAP is an attractive option to improve outcomes in men with prostate cancer due to the favourable safety profile, limited interaction with other drugs, low cost and widespread availability. Whether these medications improve patient outcomes when added to standard therapies remain controversial due to the lack of prospectively designed trials that specifically address the question and clear confounding effects. In this present analysis, we find that patients taking metformin in combination with AAP at study entry had an improved PSA-RR in both the chemotherapy-naïve (COU AA-302) and post-docetaxel (COU AA-301) treated patients. OS was prolonged in patients who are chemotherapy-naïve (COU AA-302) after adjusting for potential confounding baseline characteristics but showed only a trend towards improved OS in post-docetaxel (COU AA-301) treated patients. Statin use in combination with AAP was also associated with an improved OS in patients previously treated with docetaxel but had no effect in patients who are chemotherapy-naïve, after adjusting for baseline variables.</p>
              <p id="P23">To date, there has been only one reported randomised trial examining the use of metformin in mCRPC, the phase II TAXOMET study in which 99 patients with mCRPC were randomised to treatment with docetaxel plus metformin versus docetaxel alone in order to increase the estimated PSA-RR from 45 to 60%. No differences in the primary end-point of PSA response rate was seen [<xref rid="R15" ref-type="bibr">15</xref>] and the median OS was 24.2 months (95% CI 17.2–33.7) in the combination arm versus 19.7 months (95% CI 14.8–36.8) with docetaxel alone, which did not meet statistical significance [<xref rid="R15" ref-type="bibr">15</xref>]. A small phase II pilot study of 25 men with mCRPC demonstrated that the addition of metformin after PSA progression on abiraterone did not affect further progression and had no meaningful clinical benefit [<xref rid="R16" ref-type="bibr">16</xref>].</p>
              <p id="P24">A recent presentation of the MANSMED study (randomised single-blinded trial of metformin added to standard combined hormone treatment for men with either high-risk localised prostate cancer or metastatic castration-sensitive prostate cancer) demonstrated that patients receiving metformin had a longer time to castration-resistant disease (median 29 months, 95% CI 25 to 33) than those randomised to placebo (20 months, 95% CI 16 to 24, p = 0.01) [<xref rid="R17" ref-type="bibr">17</xref>]. This effect was most pronounced in men with high-risk localised disease and node-positive disease, marginal in those with low volume metastatic disease, and there was no benefit in those with high volume metastatic disease, and with the current follow-up interval, there was no difference in OS.</p>
              <p id="P25">We found that metformin use showed associated OS and PSA response benefit only when co-administered with AAP, which is provocative. Whilst speculative, there are several potential mechanisms of action that may explain the improved OS and PSA-RR with metformin in this post-hoc analysis. AA resistance is in part driven by increased expression of the wild type androgen receptor (AR) and AR splice variants including AR variant 7 (AR-V7) [<xref rid="R18" ref-type="bibr">18</xref>]. <italic toggle="yes">In vitro</italic> studies have demonstrated that metformin may inhibit AR-V7 and that metformin in combination with AA may lead to increased cancer cell apoptosis [<xref rid="R19" ref-type="bibr">19</xref>]. Similar results were observed between metformin and the AR antagonist enzalutamide <italic toggle="yes">in vitro</italic> [<xref rid="R20" ref-type="bibr">20</xref>]. Preclinical evidence has also implicated the role of STAT3 signalling as a mechanism of resistance to abiraterone and enzalutamide, a pathway that may be inhibited by metformin via its effect on TGF-β [<xref rid="R20" ref-type="bibr">20</xref>]. These pre-clinical results may help to explain the more consistent benefits from metformin in those randomised to AAP than those randomised to placebo. However, our findings are limited by the small number of metformin users and the lack of control over which patients received metformin thus leading to potential confounding.</p>
              <p id="P26">We found that statins were associated with a prolonged OS and improved PSA-RR in patients treated with AAP in COU-AA-301, who had previously received chemotherapy. This is in keeping with recent studies demonstrating improved OS among those treated with AAP and statin compared to statins alone [<xref rid="R21" ref-type="bibr">21</xref>-<xref rid="R23" ref-type="bibr">23</xref>]. However, we found no differences in OS in multivariate analysis or PSA response rate in patients who are chemotherapy-naïve and enrolled in the COU-AA-302 treated with AAP. Again, these findings are limited by the small number of statin users and the lack of control over which patients received statins thus leading to potential confounding.</p>
              <p id="P27">There may be several reasons for the differences seen between COU-AA-301 and 302. The beneficial effects of statins on prostate cancer survival may be moderated by timing, dose and the duration of statin use. Some studies have shown improved OS among patients taking statins prior to diagnosis [<xref rid="R24" ref-type="bibr">24</xref>] while others found improved OS if statins were used after diagnosis [<xref rid="R25" ref-type="bibr">25</xref>]. Research has also demonstrated that not all statins are equal, with increased mortality benefit for hydrophilic statins compared to hydrophobic statins perhaps due to interference in lipid raft signalling or impacts on androgen availability [<xref rid="R24" ref-type="bibr">24</xref>]. Finally, higher doses appear to have greater effect on the prostatic epithelium [<xref rid="R26" ref-type="bibr">26</xref>]. Unfortunately, data regarding statin type, dose and the duration of therapy were unavailable but could possibly explain the differential findings between COU-AA-301 and 302.</p>
              <p id="P28">There are important limitations to this study. This is exploratory hypothesis-generating post-hoc analysis of existing data and as such we chose not to perform statistical adjustments for false discovery rate. Several baseline imbalances existed between our medication groups that could affect our findings (<xref rid="SD2" ref-type="supplementary-material">Supplemental Tables 1</xref> and <xref rid="SD2" ref-type="supplementary-material">2</xref>). While adverse events by concurrent medication use are presented, we did not perform statistical comparisons due to the risk of false discovery. However, toxicities were similar between groups. We were not able to verify the causes of death which would inform whether metformin is improving prostate cancer-related death or simply decreasing other causes of death such as cardiovascular disease. Nonetheless, the association with OS in those treated with combination metformin and AAP remained significant in multivariate analysis after adjusting for these baseline imbalances, and metformin was associated with a prolonged OS when pooled across studies and treatment arms. While we demonstrate an improvement in OS and PSA response in some subgroups treated with metformin or statin, the results were inconsistent and require further study. In addition, radiographic progression-free survival data were unavailable for the cohorts involved, which may have provided correlative analyses. Finally, the subgroups of patients treated with metformin or statins are small, limiting our power to detect statistically significant differences and the takers of either drugs might simply be a surrogate for better health awareness, medical literacy and care, introducing a significant bias into the analyses.</p>
              <p id="P29">Additional prospective studies with sufficient power to examine the effects of metformin and statins on outcomes in men with prostate cancer are needed, and several large studies are currently underway such as (i) metformin versus placebo for active surveillance (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01864096" ext-link-type="uri">NCT01864096</ext-link>) (408 patients total), (ii) metformin in addition to standard of care in the mHSPC setting (STAMPEDE) (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00268476" ext-link-type="uri">NCT00268476</ext-link>) (1800 patients), (iii) aspirin/atorvastatin in addition to standard of care in mCRPC (PEACE-4) (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03819101" ext-link-type="uri">NCT03819101</ext-link>) (1210 patients), (iv) metformin in patients with mCRPC in combination with enzalutamide versus enzalutamide alone (SAKK0814) (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02640534" ext-link-type="uri">NCT02640534</ext-link>) (169 patients).</p>
            </sec>
            <sec id="S13">
              <label>5.</label>
              <title>Conclusion</title>
              <p id="P30">Although methodologically limited, our results add to the growing body of evidence that metformin may prolong OS and increase PSA-RR among patients with mCRPC treated with AAP. While our findings regarding the effects of statins on OS differed between chemotherapy-treated and chemotherapy-naïve patients, they highlight the need for further prospective and controlled clinical trials regarding the adjunctive role that these medications may play for men with mCRPC.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <label>2</label>
                <media xlink:href="NIHMS1870978-supplement-2.docx" id="d64e606" position="anchor"/>
              </supplementary-material>
              <supplementary-material id="SD2" position="float" content-type="local-data">
                <label>1</label>
                <media xlink:href="NIHMS1870978-supplement-1.docx" id="d64e609" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S14">
              <title>Grant/funding support</title>
              <p id="P31">This research in part was supported by the Tessis Family Research Fund and Hold’ em for Life Prostate Cancer Research Fund (AMJ)</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement" id="FN2">
                <p id="P32">Conflict of interest statement</p>
                <p id="P33">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p>
              </fn>
              <fn id="FN3">
                <p id="P34">Appendix A. Supplementary data</p>
                <p id="P35">Supplementary data to this article can be found online at <ext-link xlink:href="10.1016/j.ejca.2022.03.042" ext-link-type="doi">https://doi.org/10.1016/j.ejca.2022.03.042</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>[1]</label>
                <mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>CJ</given-names></name>, <name><surname>Smith</surname><given-names>MR</given-names></name>, <name><surname>De Bono</surname><given-names>JS</given-names></name>, <etal/><article-title>Abiraterone in metastatic prostate cancer without previous chemotherapy</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>368</volume>(<issue>2</issue>):<fpage>138</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">23228172</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>[2]</label>
                <mixed-citation publication-type="journal"><name><surname>De Bono</surname><given-names>JS</given-names></name>, <name><surname>Logothetis</surname><given-names>CJ</given-names></name>, <name><surname>Molina</surname><given-names>A</given-names></name>, <etal/><article-title>Abiraterone and increased survival in metastatic prostate cancer</article-title>. <source>N Engl J Med</source><year>2011</year>;<volume>364</volume>(<issue>21</issue>):<fpage>1995</fpage>–<lpage>2005</lpage>.<pub-id pub-id-type="pmid">21612468</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>[3]</label>
                <mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>JM</given-names></name>, <name><surname>Donnelly</surname><given-names>LA</given-names></name>, <name><surname>Emslie-Smith</surname><given-names>AM</given-names></name>, <name><surname>Alessi</surname><given-names>DR</given-names></name>, <name><surname>Morris</surname><given-names>AD</given-names></name>. <article-title>Metformin and reduced risk of cancer in diabetic patients</article-title>. <source>BMJ</source><year>2005</year>;<volume>330</volume>(<issue>7503</issue>):<fpage>1304</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">15849206</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>[4]</label>
                <mixed-citation publication-type="journal"><name><surname>Ruiter</surname><given-names>R</given-names></name>, <name><surname>Visser</surname><given-names>LE</given-names></name>, <name><surname>van Herk-Sukel</surname><given-names>MP</given-names></name>, <etal/><article-title>Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study</article-title>. <source>Diabetes Care</source><year>2012</year>;<volume>35</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">22100960</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>[5]</label>
                <mixed-citation publication-type="journal"><name><surname>Murtola</surname><given-names>TJ</given-names></name>, <name><surname>Tammela</surname><given-names>TL</given-names></name>, <name><surname>Lahtela</surname><given-names>J</given-names></name>, <name><surname>Auvinen</surname><given-names>A</given-names></name>. <article-title>Antidiabetic medication and prostate cancer risk: a population-based case-control study</article-title>. <source>Am J Epidemiol</source><year>2008</year>;<volume>168</volume>(<issue>8</issue>):<fpage>925</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">18700234</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>[6]</label>
                <mixed-citation publication-type="journal"><name><surname>Margel</surname><given-names>D</given-names></name>, <name><surname>Urbach</surname><given-names>DR</given-names></name>, <name><surname>Lipscombe</surname><given-names>LL</given-names></name>, <etal/><article-title>Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes</article-title>. <source>J Clin Oncol</source><year>2013</year>;<volume>31</volume>(<issue>25</issue>):<fpage>3069</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">23918942</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>[7]</label>
                <mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>JL</given-names></name>, <name><surname>Stanford</surname><given-names>JL</given-names></name>. <article-title>Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study</article-title>. <source>Cancer Causes Control</source><year>2009</year>;<volume>20</volume>(<issue>9</issue>):<fpage>1617</fpage>.<pub-id pub-id-type="pmid">19653109</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>[8]</label>
                <mixed-citation publication-type="journal"><name><surname>He</surname><given-names>K</given-names></name>, <name><surname>Hu</surname><given-names>H</given-names></name>, <name><surname>Ye</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Cui</surname><given-names>R</given-names></name>, <name><surname>Yi</surname><given-names>L</given-names></name>. <article-title>The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis</article-title>. <source>Sci Rep</source><year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>[9]</label>
                <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>MJ</given-names></name>, <name><surname>Jayalath</surname><given-names>VH</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <etal/><article-title>Association between metformin medication, genetic variation and prostate cancer risk</article-title>. <source>Prostate Cancer Prostatic Dis</source><year>2020</year>:<fpage>1</fpage>–<lpage>10</lpage>.</mixed-citation>
              </ref>
              <ref id="R10">
                <label>[10]</label>
                <mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>Y</given-names></name>, <name><surname>Zheng</surname><given-names>L</given-names></name>, <name><surname>Mei</surname><given-names>Z</given-names></name>, <etal/><article-title>The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>(<issue>59</issue>):<fpage>100449</fpage>.<pub-id pub-id-type="pmid">29245991</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>[11]</label>
                <mixed-citation publication-type="journal"><name><surname>Joentausta</surname><given-names>RM</given-names></name>, <name><surname>Rannikko</surname><given-names>A</given-names></name>, <name><surname>Murtola</surname><given-names>TJ</given-names></name>. <article-title>Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort</article-title>. <source>Prostate</source><year>2019</year>;<volume>79</volume>(<issue>6</issue>):<fpage>583</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">30652328</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>[12]</label>
                <mixed-citation publication-type="journal"><name><surname>Babcook</surname><given-names>MA</given-names></name>, <name><surname>Joshi</surname><given-names>A</given-names></name>, <name><surname>Montellano</surname><given-names>JA</given-names></name>, <name><surname>Shankar</surname><given-names>E</given-names></name>, <name><surname>Gupta</surname><given-names>S</given-names></name>. <article-title>Statin use in prostate cancer: an update</article-title>. <source>Nutr Metab Insights</source><year>2016</year>;<volume>9</volume>. NMI.S38362.</mixed-citation>
              </ref>
              <ref id="R13">
                <label>[13]</label>
                <mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>CJ</given-names></name>, <name><surname>Kheoh</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <etal/><article-title>Prognostic index model for progression-free survival in chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone</article-title>. <source>Clin Genitourin Cancer</source><year>2018</year>;<volume>16</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>7. e1</lpage>.</mixed-citation>
              </ref>
              <ref id="R14">
                <label>[14]</label>
                <mixed-citation publication-type="journal"><name><surname>Chi</surname><given-names>KN</given-names></name>, <name><surname>Kheoh</surname><given-names>T</given-names></name>, <name><surname>Ryan</surname><given-names>CJ</given-names></name>, <etal/><article-title>A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel</article-title>. <source>Ann Oncol</source><year>2016</year>;<volume>27</volume>(<issue>3</issue>):<fpage>454</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">26685010</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>[15]</label>
                <mixed-citation publication-type="journal"><name><surname>Pujalte Martin</surname><given-names>M</given-names></name>, <name><surname>Borchiellini</surname><given-names>D</given-names></name>, <name><surname>Viotti</surname><given-names>J</given-names></name>, <etal/><article-title>TAXOMET: a French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC</article-title>. <source>American Society of Clinical Oncology</source>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="R16">
                <label>[16]</label>
                <mixed-citation publication-type="journal"><name><surname>Mark</surname><given-names>M</given-names></name>, <name><surname>Klingbiel</surname><given-names>D</given-names></name>, <name><surname>Mey</surname><given-names>U</given-names></name>, <etal/><article-title>Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study</article-title>. <source>Clin Genitourin Cancer</source><year>2019</year>;<volume>17</volume>(<issue>2</issue>):<fpage>e323</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">30686756</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>[17]</label>
                <mixed-citation publication-type="journal"><name><surname>Alghandour</surname><given-names>R</given-names></name>, <name><surname>Ebrahim</surname><given-names>M</given-names></name>, <name><surname>Elshal</surname><given-names>A</given-names></name>, <name><surname>Ghobrial</surname><given-names>F</given-names></name>, <name><surname>Elzaafarany</surname><given-names>M</given-names></name>, <name><surname>Elbaiomy</surname><given-names>M</given-names></name>. <article-title>617MO Repurposing metformin as an anticancer drug: preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)</article-title>. <source>Ann Oncol</source><year>2020</year>;<volume>31</volume>:<fpage>S511</fpage>.</mixed-citation>
              </ref>
              <ref id="R18">
                <label>[18]</label>
                <mixed-citation publication-type="journal"><name><surname>Antonarakis</surname><given-names>ES</given-names></name>, <name><surname>Lu</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <etal/><article-title>AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>371</volume>(<issue>11</issue>):<fpage>1028</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">25184630</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>[19]</label>
                <mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Hussain</surname><given-names>A</given-names></name>. <article-title>Metformin enhances the anti-prostate cancer activity of abiraterone and enzalutamide</article-title>. <source>AACR</source>; <year>2016</year>.</mixed-citation>
              </ref>
              <ref id="R20">
                <label>[20]</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Q</given-names></name>, <name><surname>Tong</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <etal/><article-title>Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT</article-title>. <source>Cell Death Dis</source><year>2017</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e3007</fpage>.<pub-id pub-id-type="pmid">28837141</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>[21]</label>
                <mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>JA</given-names></name>, <name><surname>Buonerba</surname><given-names>C</given-names></name>, <name><surname>Pond</surname><given-names>G</given-names></name>, <etal/><article-title>Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study</article-title>. <source>Oncotarget</source><year>2018</year>;<volume>9</volume>(<issue>28</issue>):<fpage>19861</fpage>.<pub-id pub-id-type="pmid">29731989</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>[22]</label>
                <mixed-citation publication-type="journal"><name><surname>Harshman</surname><given-names>LC</given-names></name>, <name><surname>Werner</surname><given-names>L</given-names></name>, <name><surname>Tripathi</surname><given-names>A</given-names></name>, <etal/><article-title>The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer</article-title>. <source>Prostate</source><year>2017</year>;<volume>77</volume>(<issue>13</issue>):<fpage>1303</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">28762529</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>[23]</label>
                <mixed-citation publication-type="journal"><name><surname>Di Lorenzo</surname><given-names>G</given-names></name>, <name><surname>Sonpavde</surname><given-names>G</given-names></name>, <name><surname>Pond</surname><given-names>G</given-names></name>, <etal/><article-title>Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate</article-title>. <source>Eur Urol Focus</source><year>2018</year><month>Dec</month>;<volume>4</volume>(<issue>6</issue>):<fpage>874</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">28753882</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>[24]</label>
                <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>O</given-names></name>, <name><surname>Eberg</surname><given-names>M</given-names></name>, <name><surname>Benayoun</surname><given-names>S</given-names></name>, <etal/><article-title>Use of statins and the risk of death in patients with prostate cancer</article-title>. <source>J Clin Oncol</source><year>2013</year>;<volume>32</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">24190110</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>[25]</label>
                <mixed-citation publication-type="journal"><name><surname>Murtola</surname><given-names>TJ</given-names></name>, <name><surname>Peltomaa</surname><given-names>AI</given-names></name>, <name><surname>Talala</surname><given-names>K</given-names></name>, <etal/><article-title>Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer</article-title>. <source>Eur Urol Focus</source><year>2017</year>;<volume>3</volume>(<issue>2–3</issue>):<fpage>212</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">28753762</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>[26]</label>
                <mixed-citation publication-type="journal"><name><surname>Murtola</surname><given-names>TJ</given-names></name>, <name><surname>Syvälä</surname><given-names>H</given-names></name>, <name><surname>Pennanen</surname><given-names>P</given-names></name>, <etal/><article-title>Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL</article-title>. <source>Eur J Pharmacol</source><year>2011</year>;<volume>673</volume>(<issue>1–3</issue>):<fpage>96</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">22040920</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Fig. 1.</label>
              <caption>
                <p id="P36">Survival in patients enrolled in COU-AA-301, stratified by AAP/placebo and metformin use. AAP, acetate plus prednisone/prednisolone.</p>
              </caption>
              <graphic xlink:href="nihms-1870978-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Fig. 2.</label>
              <caption>
                <p id="P37">Survival in patients enrolled in COU-AA-302, stratified by AAP/placebo and metformin use. AAP, acetate plus prednisone/prednisolone.</p>
              </caption>
              <graphic xlink:href="nihms-1870978-f0002" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Fig. 3.</label>
              <caption>
                <p id="P38">Survival in patients enrolled in COU-AA-301, stratified by AAP/placebo and statin use. AAP, acetate plus prednisone/prednisolone.</p>
              </caption>
              <graphic xlink:href="nihms-1870978-f0003" position="float"/>
            </fig>
            <fig position="float" id="F4">
              <label>Fig. 4.</label>
              <caption>
                <p id="P39">Survival in patients enrolled in COU-AA-302, stratified by AAP/placebo and statin use. AAP, acetate plus prednisone/prednisolone.</p>
              </caption>
              <graphic xlink:href="nihms-1870978-f0004" position="float"/>
            </fig>
            <table-wrap position="float" id="T1" orientation="landscape">
              <label>Table 1</label>
              <caption>
                <p id="P40">Median overall survival by study and by statin or metformin use.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1">Metformin<break/>(median OS<break/>in months, 95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">No metformin<break/>(median OS<break/>in months, 95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">p</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Statin<break/>(median OS<break/>in months, 95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">No statin<break/>(median OS<break/>in months, 95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">HR<break/>(95% CI)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">p</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="9" align="left" valign="top" rowspan="1">COU-AA-301</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> AAP</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">19.4 (11.9-NR)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15.6 (14.7–16.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.76 (0.55–1.05)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.098</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">17.6 (15.1–19.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15.3 (14.3–16.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.76 (0.63–0.93)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.008</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Placebo</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">14.0 (10.5–19.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">11.1 (9.7–12.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.85 (0.54–1.32)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.47</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">13.2 (11.1–16.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">10.7 (9.3–12.0)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.62–1.07)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.13</td>
                  </tr>
                  <tr>
                    <td colspan="9" align="left" valign="top" rowspan="1">COU-AA-302</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> AAP</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.48–1.36)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.42</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.87 (0.63–1.21)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.41</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Placebo</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">26.6 (25.8-NR)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.68 (0.42–1.11</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.12</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NR</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">27.2 (23.9-NR)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.70 (0.52–0.96)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.02</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p id="P41">NR = not reached.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T2" orientation="landscape">
              <label>Table 2</label>
              <caption>
                <p id="P42">Multivariate analyses comparing the use of statins or metformin in COU-AA-301 and COU-AA-302.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th colspan="3" align="left" valign="top" rowspan="1">Model including metformin</th>
                    <th colspan="3" align="left" valign="top" rowspan="1">Model including statins</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">COU-AA-301</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Variable</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">HR (95% CI)</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">p</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Variable</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">HR (95% CI)</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">p</th>
                  </tr>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">
                      <bold>Abiraterone acetate plus Pred</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Metformin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.71 (0.5–1.006)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.054</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Statin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.76 (0.62–0.93)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0079</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.34 (1.1–1.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0026</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.37 (1.13–1.65)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0012</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Liver mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.99 (1.54–2.58)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Liver mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.88 (1.45–2.43)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">ECOG &gt;2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.6–2.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">ECOG &gt;2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.09 (1.61–2.71)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Albumin &lt;4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.50 (1.25–1.79)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Albumin &lt;4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.26–1.81)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.24 (1.83–2.75)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.27 (1.8–2.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Alk Phos &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.35 (1.1–1.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.003</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Alk Phos &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.33 (1.09–1.62)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.005</td>
                  </tr>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">
                      <bold>Placebo</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Metformin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.73 (0.46–1.15)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.17</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Statin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.72–1.27)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.76</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.26 (0.98–1.63)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.07</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.25 (0.97–1.62)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Liver mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.67 (1.06–2.63)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.027</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Liver mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.68 (1.07–2.65)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.025</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">ECOG &gt;2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.56 (1.06–2.30)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.025</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">ECOG &gt;2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.59 (1.08–2.34)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.019</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Albumin &lt;4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.24 (1.7–2.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Albumin &lt;4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.19 (1.68–2.86)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.99 (1.5–2.64)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.01 (1.52–2.66)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Alk Phos &gt; ULN</td>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">1.71 (1.3–2.26)</td>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">0.0001</td>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Alk Phos &gt; ULN</td>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">1.68 (1.27–2.22)</td>
                    <td align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">0.0002</td>
                  </tr>
                  <tr>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">COU-AA-302</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Variable</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">HR (95% CI)</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">p</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Variable</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">HR (95% CI)</th>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">p</th>
                  </tr>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">
                      <bold>Abiraterone acetate plus P</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Metformin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.69 (0.48–0.98)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.039</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Statin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.8–1.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.98</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.44 (1.16–1.79)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0011</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.13–1.75)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0022</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">BPI 2-3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.60 (1.25–2.04)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">BPI 2-3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.63 (1.28–2.08)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age &gt; 70</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.36 (1.1–1.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0054</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age &gt; 70</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.35 (1.08–1.69)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0078</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Baseline PSA&gt;39.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.57 (1.26–1.97)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Baseline PSA&gt;39.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.57 (1.25–1.96)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.09 (1.58–2.76)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.14 (1.62–2.83)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt;10 bone mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.01 (1.61–2.52)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt;10 bone mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.98 (1.58–2.48)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">
                      <bold>Placebo</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Metformin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.66 (0.47–0.93)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.018</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Statin</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.88 (0.71–1.08)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.22</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.69 (1.37–2.10)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LHRH2Trt</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.71 (1.38–2.12)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">BPI 2-3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.23 (0.98–1.55)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.067</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">BPI 2–3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.24 (0.98–1.55)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.066</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age &gt; 70</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.32 (1.07–1.63)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0085</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age &gt; 70</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.37 (1.11–1.69)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0032</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">Baseline PSA&gt;39.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.43 (1.16–1.77)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0008</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Baseline PSA&gt;39.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.42 (1.14–1.75)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0014</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.35 (1.02–1.79)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.03</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">LDH &gt; ULN</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.39 (1.05–1.84)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.02</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt;10 bone mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.45 (1.17–1.80)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0007</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt;10 bone mets</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.46 (1.18–1.81)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0006</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2">
                  <p id="P43">LHRH2trt – Time from LHRH administration to baseline &lt;36 months.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T3" orientation="landscape">
              <label>Table 3</label>
              <caption>
                <p id="P44">PSA response stratified by study and by statin or metformin use.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1">Metformin (% PSA response)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">No metformin<break/>(% PSA response)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">p</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Statin (% PSA response)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">No Statin<break/>(% PSA response)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">p</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">COU-AA-301</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> AAP</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">41.1%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">28.6%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.026</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">33.9%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">28.0%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.09</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Placebo</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.2%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.8%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.8%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.8%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.71</td>
                  </tr>
                  <tr>
                    <td colspan="7" align="left" valign="top" rowspan="1">COU-AA-302</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> AAP</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">72.7%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">60.0%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.046</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">60.7%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">62.1%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.73</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Placebo</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">27.9%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">23.3%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.41</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">23.3%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">24.3%</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.78</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
